Financial Data and Key Metrics Changes - Total GAAP revenue for the full year 2025 was approximately $805 million, representing approximately 20% growth year-over-year, primarily driven by the inclusion of Benihana for all twelve periods [4] - For the fourth quarter, total GAAP revenue was approximately $207 million, a decrease of 6.7% from $222 million in the prior year quarter [20] - Full year 2025 comparable sales declined approximately 3.7%, reflecting continued pressure across the full-service dining segment [5] - Adjusted EBITDA attributable to The ONE Group Hospitality was $28.1 million, a decrease of 9.5% compared to $31 million in the prior year quarter [28] Business Line Data and Key Metrics Changes - Year-to-date, both Benihana and STK reported positive sales, while Kona Grill's turnaround is gaining traction, with transactions positive, representing the best same-store performance for the brand since early 2023 [8] - Consolidated comparable sales for the fourth quarter declined approximately 1.8%, but all brands demonstrated sequential improvement during the quarter [7] - Restaurant operating profit, excluding closed Grille Concepts, was $38.9 million or 19.5% of owned restaurant net revenue, improving by 10 basis points from the prior year quarter [23] Market Data and Key Metrics Changes - The fourth quarter had one fewer operating day due to a fiscal calendar shift, impacting revenue comparisons [6] - Sales of managed STK in Las Vegas have notably improved quarter to date, indicating regional performance variations [22] Company Strategy and Development Direction - The company aims to accelerate same-store sales through execution, with a target of a 1%-3% increase for 2026 [9] - Capital-efficient growth is a priority, with significant asset-light development agreements secured for Benihana locations [14] - The company is focusing on operational excellence, culinary innovation, and targeted marketing as key pillars for growth [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting a strengthened portfolio and expanded franchise capabilities [31] - Consumer confidence remains low, but the company is seeing positive trends in traffic and sales due to operational initiatives and value offerings [67] - The company projects total GAAP revenues between $840 million and $855 million for fiscal year 2026, reflecting anticipated consolidated comparable sales growth [30] Other Important Information - The company has strategically shifted protein sourcing and contracted beef pricing through September 2026, providing cost certainty and margin improvement [11] - The company plans to open 6-10 new venues in 2026, maintaining capital discipline and focusing on high-quality markets [30] Q&A Session Summary Question: What are the strategic priorities for Benihana for the balance of this year? - The priority for Benihana includes marketing initiatives, digital engagement, and improving operational efficiency and guest experience [33] Question: What caused the revenue shortfall in the fourth quarter? - The revenue shortfall was attributed to slower table turns at Benihana and the impact of the fiscal calendar shift [41][42] Question: What are the remaining cost synergies from the Benihana acquisition? - Remaining synergies include improved distribution, beef purchasing power, and consolidation of other supply costs [44][46] Question: Have recent world events impacted traffic? - So far, there has been no significant impact on traffic, but the situation is being monitored closely [47] Question: Were there notable regional differences in traffic? - Regional differences narrowed in the fourth quarter, with improved performance in Las Vegas due to targeted marketing [51][52] Question: What is the expected same-store sales guidance for the full year? - The guidance includes a pricing increase of around 5%-6% for the year, with a focus on value [53][79] Question: How is the company managing protein costs? - The company is seeing favorable conditions for frozen seafood and is managing other protein costs based on market conditions [55] Question: What is the timeline for the conversion of restaurants? - The company plans to reopen converted restaurants by July 2026, with construction cycles expected to be relatively short [59] Question: What is the outlook for G&A costs? - G&A costs are projected to increase due to anticipated bonuses and operational targets [85]

Summary of Surgery Partners FY Conference Call (March 10, 2026) Company Overview - **Company**: Surgery Partners (NasdaqGS:SGRY) - **Industry**: Healthcare, specifically focused on surgical facilities and outpatient care Key Points and Arguments Market Dynamics - The company operates as an independent surgical facility amidst large integrated nonprofit systems that are moving away from Medicare Advantage (MA) contracts, impacting patient access and revenue [1] - There is a noted growth of 18% in high acuity procedures, but this growth was primarily driven by Medicare patients, leading to lower net revenue despite increased case volume [2][3] - The company is experiencing pressure from the Affordable Care Act (ACA) exchange patients, which affects their commercial patient mix and overall revenue [3][9] Financial Performance - Total case volumes fell below expectations due to payer mix issues, yet the company exceeded the high end of revenue guidance, indicating strong performance in high acuity cases [8] - The company is actively working on cost reduction and efficiency improvements to address margin compression faced by physicians [5][10] Strategic Initiatives - The company is focused on optimizing its portfolio by potentially divesting from larger facilities that have higher debt loads and lower free cash flow conversion [24][25] - A share repurchase program of $200 million has been authorized, indicating confidence in future cash flows from portfolio optimization efforts [26][28] Guidance and Future Outlook - The company has adopted a conservative approach to guidance for 2026, excluding unannounced M&A, while maintaining a target of at least $200 million for capital deployment [12][15] - There is an expectation that some market pressures will take time to resolve, particularly regarding MA and commercial access [9][11] Policy and Regulatory Environment - The company supports site neutrality in healthcare payments, believing that their facilities can provide care at a lower cost compared to traditional acute care settings [30][31] - The expiration of enhanced ACA subsidies has had a localized impact on patient volumes, particularly in one market where exchange patients were significant [33][36] Cost Structure and Anesthesia Challenges - The relationship between labor costs, anesthesia costs, and shifts in government payer mix is complex, with anesthesiologists facing reimbursement challenges that affect coverage and costs for the company [38][40] - The company is exploring ways to manage anesthesia costs more effectively, given the significant disparity in reimbursement rates between Medicare and commercial payers [39][40] Additional Important Insights - The company emphasizes the importance of physician partnerships and the need for better coordination to capture commercial patients effectively [7] - There is a strong focus on maintaining high patient experience and outcomes, which are critical for attracting and retaining physician partners [6][10] - The company believes that even in a potential economic slowdown, their value proposition as a lower-cost provider positions them well in the market [18][20]

Core Viewpoint - The article discusses the investment strategy and insights of a seasoned stock analyst with over 20 years of experience, emphasizing a focus on equity valuation, market trends, and portfolio optimization to identify high-growth investment opportunities [1]. Group 1: Analyst Background - The analyst has extensive experience in quantitative research, financial modeling, and risk management, previously serving as a Vice President at Barclays [1]. - The analyst leads teams in model validation, stress testing, and regulatory finance, showcasing expertise in both fundamental and technical analysis [1]. - The analyst collaborates with a research partner, co-authoring investment research that combines their strengths for high-quality, data-driven insights [1]. Group 2: Investment Approach - The investment approach integrates rigorous risk management with a long-term perspective on value creation [1]. - There is a particular interest in macroeconomic trends, corporate earnings, and financial statement analysis, aimed at providing actionable ideas for investors [1].

Financial Data and Key Metrics Changes - The company reported full year net revenue of $3.3 billion, up 6.2% year-over-year, with same facility revenue growth of 4.9% [4][25] - Full year Adjusted EBITDA was $526 million, up 3.5% year-over-year, but significantly below expectations, with an Adjusted EBITDA margin of 15.9%, reflecting 40 basis points of margin compression [4][26] - Fourth quarter revenue grew 2.4% to $885 million, with Adjusted EBITDA of $156.9 million and a margin of 17.7% [24][25] Business Line Data and Key Metrics Changes - The company performed nearly 670,000 surgical cases in 2025, a 2% increase from 2024, with same facility case growth of 1.3% in the fourth quarter [7][24] - Orthopedic cases grew significantly, with total joint replacements increasing by 15% in the fourth quarter and 19% year-to-date compared to the previous year [8] - Physician recruitment remained strong with almost 700 physicians recruited in 2025, although some transitions affected payer mix [9] Market Data and Key Metrics Changes - The company experienced a decline in commercial payer mix, particularly in three surgical hospital markets, which faced slower case growth and shifts in payer dynamics [5][10] - The fourth quarter saw a significant pressure on payer mix, with a 370 basis point decline in commercial patients compared to the previous year [79] Company Strategy and Development Direction - The company remains committed to its growth algorithm, focusing on organic, de novo, and acquired growth, while optimizing its portfolio to enhance shareholder value [6][12] - M&A is a critical component of the growth strategy, with a disciplined approach to capital allocation and a strong pipeline of opportunities [13][35] - The company is executing a comprehensive portfolio optimization strategy aimed at improving balance sheet strength without sacrificing growth [15][36] Management's Comments on Operating Environment and Future Outlook - Management acknowledged significant headwinds in the second half of the year, particularly in surgical hospitals, but expressed confidence in long-term growth opportunities [5][6] - The initial guidance for 2026 is net revenue of $3.35 billion to $3.45 billion, with Adjusted EBITDA of at least $530 million, reflecting anticipated headwinds [18][33] - Management emphasized the importance of addressing near-term challenges while remaining optimistic about structural tailwinds in the ASC market [20][36] Other Important Information - The board authorized a share repurchase program of up to $200 million, reflecting confidence in the company's future and capital allocation strategy [22][84] - The company appointed Lloyd Dean as a new director, bringing valuable healthcare experience to support growth [22] Q&A Session Summary Question: Challenges of headwinds and volume dynamics - Management acknowledged the challenges but emphasized the value created in the healthcare space and the belief in growth opportunities despite current pressures [40][41] Question: Recovery of surgical hospital markets - Management indicated that while there are pressures, they do not expect a repeat of the current issues and are focused on turnaround plans [70] Question: Breakdown of same-store revenue guidance - The breakdown between price and volume in the 3% same-store revenue guidance is roughly even [60] Question: Capital deployment and share buyback - Management stated that capital deployment will be measured against all potential uses, including share buybacks, while focusing on deleveraging [53][82]

Financial Data and Key Metrics Changes - The company reported full year net revenue of $3.3 billion, up 6.2% year-over-year, with same facility revenue growth of 4.9% [4][24] - Full year Adjusted EBITDA was $526 million, up 3.5% year-over-year, but significantly below expectations, with an Adjusted EBITDA margin of 15.9%, reflecting 40 basis points of margin compression [4][26] - Fourth quarter revenue grew 2.4% to $885 million, with same facility total revenue increasing 3.5% [24][25] Business Line Data and Key Metrics Changes - The company performed nearly 670,000 surgical cases in 2025, a 2% increase from 2024, with 1.3% same facility case growth in the fourth quarter [7][24] - Orthopedic cases grew significantly, with total joint replacements increasing 15% in the fourth quarter and 19% year-to-date compared to the previous year [8] - The company faced challenges in three surgical hospital markets, which experienced slower case growth and shifts in payer mix, impacting overall performance [5][10] Market Data and Key Metrics Changes - The payer mix softened during the fourth quarter, with a decline in commercial patients compared to historical experience, leading to pressure on revenue [25][41] - The company noted that the pressure on payer mix was concentrated in its surgical hospitals, while its ambulatory surgical centers (ASCs) performed in line with historical trends [79] Company Strategy and Development Direction - The company remains committed to its growth strategy, focusing on organic growth, acquisitions, and de novo facility development, with a disciplined approach to capital allocation [6][12] - A portfolio optimization strategy is being executed to unlock value and drive sustained success, with plans to divest certain facilities that do not align with core strategies [15][16] - The company anticipates opening additional de novo facilities in high-growth markets, with a focus on higher acuity specialties [13][31] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in the second half of the year but expressed confidence in the long-term growth opportunities driven by structural market dynamics [6][20] - The initial guidance for 2026 includes net revenue of $3.35 billion to $3.45 billion, representing single-digit year-over-year growth, and at least $530 million in Adjusted EBITDA [18][33] - Management emphasized the importance of addressing near-term headwinds while remaining optimistic about the structural tailwinds supporting long-term growth in the ASC market [20][36] Other Important Information - The board authorized a share repurchase program of up to $200 million, reflecting confidence in the company's future and capital allocation strategy [22][84] - The company appointed Lloyd Dean as a new director, bringing valuable healthcare experience to support growth and partnerships [23] Q&A Session Summary Question: How to think through the challenges of headwinds and payer mix dynamics? - Management highlighted the importance of their value proposition in the market and expressed confidence in their growth algorithm despite current challenges [40][41] Question: What is the weighting of issues in the three specific markets mentioned? - Management explained that the issues are distinct to each market, with plans in place to address them and a belief that these pressures are not expected to repeat [44][51] Question: How does the company plan to balance capital deployment with a leveraged balance sheet? - Management indicated a focus on maximizing shareholder value through disciplined capital allocation, including M&A, debt repayment, and share buybacks [53][56] Question: What is the breakdown between price and volume in the 3% same-store revenue guide? - Management stated that the breakdown is roughly even between price and volume [60] Question: When can positive signs be expected from physician partners regarding mix? - Management noted that improvements are expected in the back half of the year as strategies are implemented to enhance access for commercial patients [62][63]

Financial Data and Key Metrics Changes - The company reported full year net revenue of $3.3 billion, up 6.2% year-over-year, with same facility revenue growth of 4.9% [4][24] - Full year Adjusted EBITDA was $526 million, up 3.5% year-over-year, but below expectations, with an Adjusted EBITDA margin of 15.9%, reflecting 40 basis points of margin compression [4][25] - Fourth quarter revenue grew 2.4% to $885 million, with Adjusted EBITDA of $156.9 million and a margin of 17.7% [23][25] Business Line Data and Key Metrics Changes - The company performed nearly 670,000 surgical cases in 2025, a 2% increase from 2024, with same facility case growth of 1.3% in the fourth quarter [6][23] - Orthopedic cases grew significantly, with total joint replacements increasing by 15% in the fourth quarter and 19% year-to-date compared to the previous year [7] - The company faced challenges in three surgical hospital markets, which experienced slower case growth and shifts in payer mix, impacting overall performance [5][9] Market Data and Key Metrics Changes - The payer mix softened during the fourth quarter, with a decline in commercial patients compared to historical trends, primarily affecting surgical hospitals [24][41] - The company noted that the pressure on payer mix was concentrated in specific markets, with some competitors opting to limit access to Medicare Advantage patients [46][81] Company Strategy and Development Direction - The company remains committed to its growth strategy, focusing on organic growth, acquisitions, and optimizing its portfolio to enhance shareholder value [6][12] - A portfolio optimization strategy is underway, aimed at divesting non-core facilities and enhancing operational efficiency [13][15] - The company plans to continue investing in de novo facilities, with eight openings in 2025 and more in the pipeline, targeting high-growth markets [12][31] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in the second half of 2025 but expressed confidence in the long-term growth potential of the business [5][10] - The initial guidance for 2026 includes net revenue of $3.35 billion to $3.45 billion, reflecting single-digit growth, and at least $530 million in Adjusted EBITDA [16][33] - Management emphasized the need for improved execution and cost management to address near-term headwinds while remaining optimistic about structural growth opportunities [18][19] Other Important Information - The company authorized a share repurchase program of up to $200 million, reflecting confidence in future growth and capital allocation strategy [20][56] - New leadership has been appointed to support operational improvements in underperforming facilities [10][73] Q&A Session Summary Question: Challenges and Volume Outlook - A question was raised regarding the balance between conservative volume expectations and the belief in strong fundamentals [40] - Management responded by reiterating confidence in the growth algorithm and the value created within the healthcare system [41][42] Question: Payer Mix Dynamics - Inquiry about the payer mix situation and its impact on volumes, particularly regarding Medicare and commercial patients [40] - Management acknowledged the unique pressures faced in specific markets and expressed optimism about returning to a balanced payer mix [45][54] Question: Capital Deployment and Share Buyback - A question was posed about balancing capital deployment with the share buyback program [55] - Management clarified that the share buyback is part of a measured approach to maximize shareholder value while considering debt reduction [56][85] Question: Recovery of Surgical Hospital Markets - A question was asked about the recovery assumptions for surgical hospital markets [70] - Management indicated that while there are pressures, they do not expect a repeat of the previous year's challenges and are focused on turnaround plans [73][81]

Financial Data and Key Metrics Changes - The fourth quarter consolidated volume was 4.2 billion gallons, down 5% year-over-year, with full-year volume totaling 16.9 billion gallons, down approximately 4% [16] - Fourth quarter gross profit was $235 million, down 9% year-over-year, and full-year gross profit was $948 million, down 8% from 2024 [16][17] - Total non-GAAP adjustments in the fourth quarter were $325 million, with significant impairments primarily within the land segment [15] Business Line Data and Key Metrics Changes - Aviation volumes in the fourth quarter were 1.8 billion gallons, down 5% year-over-year, but gross profit increased approximately 8% to $130 million due to the Universal Trip Support acquisition [17][18] - Land volumes declined 9% year-over-year in the fourth quarter, with gross profit down 32% to $71 million, driven by unfavorable market conditions and exit activities [20][21] - Marine volumes were approximately 4.1 million metric tons in the fourth quarter, flat year-over-year, while gross profit increased 2% to $35 million [23] Market Data and Key Metrics Changes - The company is focusing on North America for its land business, emphasizing higher margin activities such as cardlock and retail, as well as natural gas [8][10] - The exit from European power and energy management businesses shifts focus to core areas that deliver consistent profitability [10] Company Strategy and Development Direction - The company is reshaping its portfolio to concentrate on businesses that deliver attractive and predictable returns, enhancing financial discipline and operational efficiency [6][12] - The acquisition of Universal Weather and Aviation's trip support services is expected to strengthen the company's role in global aviation services [7] - The strategic shift in the land segment aims to enhance returns and improve profitability, with a focus on cardlock, retail, and natural gas [22] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that the fourth quarter performance fell short of expectations due to competitive pressures and underperformance in certain business lines [12] - The outlook for 2026 reflects confidence in the structural changes made, aiming for more consistent performance and growth in core businesses [13][30] - Management expects adjusted EPS for 2026 to be in the range of $2.20-$2.40, indicating solid year-over-year growth [27] Other Important Information - The company generated $34 million of operating cash flow and $13 million of free cash flow in the fourth quarter, with full-year free cash flow totaling $227 million [28] - An incremental $150 million share repurchase authorization was approved, reflecting confidence in the business [29] Q&A Session Summary Question: Impact of Universal Trip acquisition and tank wagon business sale - The Universal Trip Support business is expected to contribute approximately $70 million in gross profit for 2026, while the tank wagon business exit will shed about 1 billion gallons of volume [34][36] Question: Seasonality in land business after exiting European operations - The seasonality in the land business is expected to improve, with the main seasonality now related to aviation demand [41][42] Question: New model for managing fuel operations with independent operators - The new hybrid model allows for better cash flow and higher margins, with opportunities for growth in the convenience store space [46][47] Question: Competitive pressure in aviation and its implications - While competitive pressure is present, management is optimistic about finding new opportunities to expand airport locations and drive additional volume [50][51] Question: Factors for rebound in marine business - The marine business is influenced by macro factors such as price and volatility, with expectations for stability in 2026 [53][54]

Financial Data and Key Metrics Changes - Q4 consolidated volume was 4.2 billion gallons, down 5% year-over-year, with full-year volume totaling 16.9 billion gallons, down approximately 4% [16] - Q4 gross profit was $235 million, down 9% year-over-year, and full-year gross profit was $948 million, down 8% from 2024 [16][17] - Adjusted operating expenses in Q4 were $186 million, down 6% year-over-year, and for the full year, adjusted operating expenses declined approximately 7% to $718 million [24][25] Business Line Data and Key Metrics Changes - Aviation Q4 volumes were 1.8 billion gallons, down 5% year-over-year, but gross profit increased approximately 8% year-over-year to $130 million due to the Universal Trip Support acquisition [17][18] - Land Q4 volumes declined 9% year-over-year, with gross profit at $71 million, down 32% year-over-year, driven by unfavorable market conditions and exit activities [20][21] - Marine Q4 volumes were approximately 4.1 million metric tons, flat year-over-year, while Q4 gross profit increased 2% year-over-year to $35 million [23] Market Data and Key Metrics Changes - The company is focusing on North America for its land business, particularly in higher margin areas such as cardlock and retail activities, as well as natural gas [8][10] - The exit from European power and energy management businesses allows the company to concentrate on core areas that deliver consistent profitability [10][12] Company Strategy and Development Direction - The company is reshaping its portfolio to focus on businesses that deliver attractive and predictable returns, with a commitment to operational excellence and disciplined capital allocation [6][7] - The acquisition of Universal Weather and Aviation's trip support services is expected to enhance capabilities in flight support and strengthen the global aviation services role [7] - The strategic shift in the land segment aims to improve profitability and transparency regarding long-term growth potential [9][11] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that Q4 performance fell short of expectations due to competitive pressures and underperformance in certain business lines [12] - The outlook for 2026 reflects confidence in structural changes that simplify the business and enhance focus on core growth areas [13] - Management expects adjusted operating income to nearly double in the refocused land business, despite lower volumes and gross profit [23] Other Important Information - Total non-GAAP adjustments in Q4 were $325 million, primarily due to non-cash intangible and asset impairments [15] - The company generated $34 million of operating cash flow and $13 million of free cash flow in Q4, with full-year free cash flow at $227 million [28] Q&A Session Summary Question: Can you discuss the scale of revenues and operating income from the Universal Trip acquisition? - The gross profit for the Universal Trip Support business is approximately $70 million, with the impact on 2026 expected to be around that figure [35] Question: What impact should we expect from the sale of the tank wagon business? - The company is shedding about 1 billion gallons worth of volume and expects to receive about $100 million from the transaction [36] Question: How will the exit from European businesses affect seasonality in land? - The seasonality in land is expected to improve significantly with the exit of the UK land business, making the business more balanced [41][43] Question: Can you elaborate on the new model of owning and managing fuel operations? - The new hybrid model allows for better cash flow and higher margins by owning the fuel and partnering with independent operators for convenience stores [47][48] Question: What are the expectations for the marine business rebound? - The marine business is stable but relies on macro factors such as price and volatility, which are currently low [53][54]

Financial Data and Key Metrics Changes - Mativ's full year 2025 net sales were just under $2 billion, up 2.5% organically and modestly on a reported basis compared to the prior year [17] - Adjusted EBITDA for 2025 was $225 million, up 3% year-over-year, with Q4 Adjusted EBITDA increasing 19% to $53.5 million [18][22] - Free cash flow reached a record $94 million in 2025, more than doubling the previous year's result [22][23] Business Line Data and Key Metrics Changes - Filtration and Advanced Materials (FAM) segment net sales were up over 5% year-over-year, with adjusted EBITDA increasing by 26% [19][20] - Sustainable & Adhesive Solutions (SAS) segment sales were largely flat year-over-year on an organic basis, with adjusted EBITDA increasing by more than 8% [20][21] Market Data and Key Metrics Changes - The company faced headwinds in certain markets, particularly in automotive labels and release liners in Europe, impacting the SAS segment [33][49] - Despite challenges, FAM segment showed growth in transportation and industrial filtration, indicating resilience in specific market categories [35][56] Company Strategy and Development Direction - Mativ's strategy focuses on three pillars: enhancing commercial excellence, strengthening the balance sheet, and optimizing the portfolio [6][10] - The company aims to leverage AI as a foundational enterprise capability to drive productivity and operational improvements [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a complex macroeconomic environment with dynamic trade movements and geopolitical instability, emphasizing the need for agility [12][28] - For 2026, the company anticipates continued focus on cost-saving initiatives, with expected savings of $15 million to $20 million [27] Other Important Information - Mativ reduced net debt by over $60 million in 2025, ending the year with a net leverage ratio of 4.2 times [23][40] - The company plans to invest $45 million in capital expenditures in 2026, split between growth and efficiency projects [25] Q&A Session Summary Question: Details on headwinds within SAS and potential catalysts for improvement - Management noted weakness in automotive tapes and release liners, but expressed optimism about growth opportunities in other categories and regions [33][34] Question: Sustainability of momentum in FAM segment - Management highlighted ongoing investments and improvements in the FAM segment, expecting continued growth despite market challenges [35][36] Question: Free cash flow expectations for 2026 - Management indicated a small decline in free cash flow from 2025's record levels, primarily due to funding growth initiatives [37][38] Question: Guidance for Q1 and market conditions - Management expects low single-digit volume growth in Q1, with EBITDA growth of 15%-20% despite soft demand [45][52] Question: Commercial pipeline performance relative to market - Management emphasized a focused approach to the commercial pipeline, with strong customer collaboration and improved operational metrics [56]

Financial Data and Key Metrics Changes - In Q4 2025, IFF generated revenue of nearly $2.6 billion, with a 1% growth compared to a 6% year-ago comparable, and a 4% increase on a two-year average basis [12][10] - EBITDA totaled $437 million for Q4, a 7% increase, with an EBITDA margin increase of 90 basis points to 16.9% [12][10] - For the full year 2025, IFF achieved 7% EBITDA growth with 100 basis points of margin expansion [11] Business Line Data and Key Metrics Changes - Taste segment sales increased 2% to $588 million, with EBITDA up 17% to $94 million [13] - Health and Biosciences segment sales grew 5% to $589 million, with EBITDA increasing 20% to $155 million [15] - Scent segment sales rose 4% to $610 million, with EBITDA increasing 1% to $106 million [16] - Food ingredients sales decreased 4% to $802 million, but EBITDA grew 10% with a 150 basis points margin expansion [11][15] Market Data and Key Metrics Changes - The performance in North America for the Taste segment showed high single-digit growth driven by new wins [13] - Health and Biosciences saw strong growth in food biosciences and animal nutrition, both achieving double-digit growth [15] - The Scent segment's fine fragrance experienced double-digit growth, while fragrance ingredients faced declines due to market softness [11][16] Company Strategy and Development Direction - IFF is focusing on high-value, innovation-driven businesses, having divested from lower-margin segments [8][9] - The company is pursuing a sale for its food ingredients business to optimize its portfolio [8][19] - IFF aims to enhance competitiveness through investments in innovation, digital transformation, and operational excellence [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for 2026, expecting sales growth in the range of $10.5 billion to $10.8 billion, representing 1%-4% growth [20] - The company anticipates EBITDA for 2026 to be between $2.05 billion and $2.15 billion, reflecting 3%-8% growth [21] - Management acknowledged ongoing macroeconomic uncertainties but emphasized confidence in achieving profitable growth [10][20] Other Important Information - Cash flow from operations totaled $850 million for the full year, with CapEx at $594 million [16] - The company returned $409 million to shareholders through dividends and share repurchases [17] - IFF's net debt to credit-adjusted EBITDA improved to 2.6 times, down from 3.8 times in 2024 [18] Q&A Session Summary Question: Assumptions around price and volume in 2026 - Management indicated that expected growth for 2026 is volume-driven, with incremental margins on volumes around 30%-35% depending on the segment [30][31] Question: Top and bottom end of the 1%-4% currency neutral sales outlook - Management expressed cautious optimism, driven by a strong pipeline and customer emphasis on volume growth [33][34] Question: Early interest in the sale of food ingredients - Management confirmed strong interest from both strategic and private equity firms, with proceeds expected to be used for share buybacks and debt reduction [39][41] Question: Price dynamics in the scent segment - Management noted that pricing was flat year-over-year, with margin pressure primarily from input costs [43][44] Question: Health and biosciences margin uplift - Management attributed strong performance to volume growth and productivity, with expectations for stabilization and growth in the health business [46][48] Question: Free cash flow expectations for 2026 - Management expects meaningful improvement in cash flow driven by profitability growth and working capital management [50][52] Question: R&D efforts and innovation metrics - Management highlighted a $100 million investment in innovation capabilities, with expected benefits materializing in the second half of 2026 [56][58] Question: Reformulation opportunities in the marketplace - Management noted ongoing reformulation trends, viewing them as opportunities for growth in healthier product offerings [88][90]